News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,970 Results
Type
Article (14128)
Company Profile (282)
Press Release (250560)
Section
Business (79524)
Career Advice (154)
Deals (13234)
Drug Delivery (35)
Drug Development (50413)
Employer Resources (32)
FDA (5712)
Job Trends (5145)
News (144409)
Policy (10029)
Tag
Academia (910)
Alliances (21627)
Alzheimer's disease (796)
Antibody-drug conjugate (ADC) (75)
Approvals (5714)
Artificial intelligence (93)
Bankruptcy (102)
Best Places to Work (4579)
Biotechnology (232)
Breast cancer (130)
Cancer (1113)
Cardiovascular disease (88)
Career advice (133)
CAR-T (92)
Cell therapy (272)
Clinical research (40572)
Collaboration (436)
Compensation (184)
COVID-19 (1027)
C-suite (117)
Cystic fibrosis (74)
Data (1151)
Diabetes (105)
Diagnostics (1296)
Earnings (29223)
Events (47710)
Executive appointments (353)
FDA (6219)
Funding (414)
Gene editing (76)
Gene therapy (199)
GLP-1 (338)
Government (1072)
Healthcare (6579)
Infectious disease (1078)
Inflammatory bowel disease (105)
IPO (7252)
Job creations (861)
Job search strategy (128)
Layoffs (196)
Legal (1383)
Lung cancer (164)
Manufacturing (103)
Medical device (2583)
Medtech (2584)
Mergers & acquisitions (6216)
Metabolic disorders (315)
Neuroscience (1108)
NextGen: Class of 2025 (2017)
Non-profit (857)
Northern California (1340)
Obesity (166)
Opinion (96)
Parkinson's disease (89)
Patents (86)
People (25377)
Phase I (14318)
Phase II (18875)
Phase III (11931)
Pipeline (504)
Postmarket research (852)
Preclinical (5996)
Radiopharmaceuticals (209)
Rare diseases (248)
Real estate (1418)
Regulatory (8442)
Research institute (934)
Series A (82)
Southern California (1188)
Startups (1969)
United States (10537)
Vaccines (189)
Weight loss (96)
Date
Today (9)
Last 7 days (339)
Last 30 days (1529)
Last 365 days (20417)
2025 (2645)
2024 (20565)
2023 (22429)
2022 (26875)
2021 (27876)
2020 (23434)
2019 (16257)
2018 (11762)
2017 (13759)
2016 (11851)
2015 (14406)
2014 (10426)
2013 (7508)
2012 (7538)
2011 (7634)
2010 (7433)
Location
Africa (148)
Asia (17110)
Australia (2893)
California (3048)
Canada (965)
China (269)
Colorado (116)
Connecticut (130)
Delaware (72)
Europe (36864)
Florida (348)
Georgia (91)
Illinois (192)
Indiana (73)
Maryland (396)
Massachusetts (2387)
Minnesota (119)
New Jersey (762)
New York (835)
North Carolina (476)
Northern California (1340)
Ohio (98)
Pennsylvania (577)
South America (208)
Southern California (1188)
Texas (337)
Washington State (291)
264,970 Results for "stoke therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.
February 18, 2025
·
2 min read
·
Dan Samorodnitsky
Genetown
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics, Inc. today announced that management will present at the following upcoming investor conferences.
June 3, 2024
·
1 min read
Press Releases
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
·
1 min read
Press Releases
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
February 19, 2025
·
16 min read
Business
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Stoke Therapeutics, Inc. today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.
April 29, 2024
·
5 min read
Business
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics, Inc. today announced the appointment of Jason Hoitt as Chief Commercial Officer.
April 17, 2024
·
6 min read
Press Releases
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
December 4, 2024
·
8 min read
Business
Stoke Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
May 6, 2024
·
13 min read
Press Releases
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 5, 2024
·
11 min read
Press Releases
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
January 7, 2025
·
2 min read
1 of 26,497
Next
